Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems
Study sponsor: Supernus Pharmaceuticals, Inc. · SUPN
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2009-09-23Actual
Enrollment · participants78Actual
Source updated2025-12-09Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.